← Back to home

Pathologic stage III HPV-mediated (P16-positive) oropharyngeal carcinoma ajcc V8

Clinical trials for Pathologic stage III HPV-mediated (P16-positive) oropharyngeal carcinoma ajcc V8 explained in plain language.

Never miss a new study

Get alerted when new Pathologic stage III HPV-mediated (P16-positive) oropharyngeal carcinoma ajcc V8 trials appear

Sign up with your email to follow new studies for Pathologic stage III HPV-mediated (P16-positive) oropharyngeal carcinoma ajcc V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Trials to join now! 2 Completed 1

New combo therapy shows promise for Tough-to-Treat head and neck cancer

Disease control Completed

This study tested whether giving the immunotherapy drug durvalumab alongside radiation works better than the standard cetuximab plus radiation for people with advanced head and neck cancer who cannot take the usual chemotherapy drug cisplatin. A total of 196 adults took part. The…

Matched conditions: PATHOLOGIC STAGE III HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8

Phase 2/3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control

Last updated Aug 29, 2026 00:00 UTC

Pathologic stage III HPV-mediated (P16-positive) oropharyngeal carcinoma ajcc V8

Get alerted when new Pathologic stage III HPV-mediated (P16-positive) oropharyngeal carcinoma ajcc V8 trials appear

New combo therapy shows promise for Tough-to-Treat head and neck cancer